FDA Approved Products
4,491 products with lifecycle intelligence, competitive pressure scores, and patent timelines.
CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER
ceftriaxone
LOE Approaching
B. Braun
INJECTION · INJECTABLE
the following infections caused by susceptible isolates of the designated bacteria: Lower Respiratory Tract Infections ()
2005
NDA30/100
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER
cefuroxime and dextrose
LOE Approaching
B. Braun
INJECTION · INJECTABLE
including pneumoniacaused by Streptococcus pneumoniae+4
2001
NDA30/100
CEFZIL
cefprozil
LOE Approaching
Engine Biosciences
ORAL · FOR SUSPENSION
development of drug-resistant bacteriamaintain the effectiveness of cefprozil tablets+4
1991
NDA30/100
CEFZIL
cefprozil
LOE Approaching
Engine Biosciences
ORAL · TABLET
development of drug-resistant bacteriamaintain the effectiveness of cefprozil tablets+4
1991
NDA30/100
CELEBREX
celecoxib
LOE Approaching
Pfizer
ORAL · CAPSULE
Rheumatoid Arthritis
1999
SMNDA30/100
CELEBREX
celecoxib
LOE Approaching
Viatris (2)
ORAL · CAPSULE
Rheumatoid Arthritis
1998
SMNDA30/100
CELESTONE
betamethasone
LOE Approaching
Merck & Co.
ORAL · TABLET
dermatomyositispolymyositis+17
1961
NDA30/100
CELESTONE
betamethasone
LOE Approaching
Merck & Co.
ORAL · SYRUP
dermatomyositispolymyositis+17
1964
NDA30/100
CELESTONE
betamethasone sodium phosphate
LOE Approaching
Merck & Co.
INJECTION · INJECTABLE
dermatomyositispolymyositis+17
1974
NDA30/100
CELESTONE SOLUSPAN
betamethasone acetate and betamethasone sodium phosphate
LOE Approaching
Merck & Co.
INJECTION · INJECTABLE
dermatomyositispolymyositis+17
1965
NDA30/100
CELEXA
citalopram hydrobromide
LOE Approaching
Forest Devices
ORAL · SOLUTION
major depressive disorder (MDD) in adults ()
1999
NDA30/100
CELEXA
citalopram
LOE Approaching
AbbVie
ORAL · TABLET
major depressive disorder (MDD) in adults ()
1998
NDA30/100
CELLCEPT
mycophenolate mofetil
LOE Approaching
Roche
ORAL · FOR SUSPENSION
organ rejectioncombination with other immunosuppressants+4
1998
NDA30/100
CELLCEPT
mycophenolate mofetil
LOE Approaching
Roche
ORAL · CAPSULE
organ rejectioncombination with other immunosuppressants+4
1995
NDA30/100
CELLCEPT
mycophenolate mofetil hydrochloride
LOE Approaching
Roche
INJECTION · INJECTABLE
organ rejectioncombination with other immunosuppressants+4
1998
NDA30/100
CELLCEPT
mycophenolate mofetil
LOE Approaching
Roche
ORAL · TABLET
organ rejectioncombination with other immunosuppressants+4
1997
NDA30/100
CELONTIN
methsuximide
LOE Approaching
Pfizer
ORAL · CAPSULE
1957
NDA30/100
CENESTIN
estrogens, conjugated synthetic a
LOE Approaching
Aspen Surgical
ORAL · TABLET
1999
NDA30/100
CENTANY
mupirocin
LOE Approaching
Design Pharmaceuticals
TOPICAL · OINTMENT
2002
NDA30/100
CENTRAX
prazepam
LOE Approaching
Pfizer
ORAL · CAPSULE
1979
NDA30/100
CEPHULAC
lactulose
LOE Approaching
Sanofi
ORAL, RECTAL · SOLUTION
1976
NDA30/100
CEPTAZ
ceftazidime
LOE Approaching
GSK
INJECTION · INJECTABLE
the following infections caused by designated susceptible Gram-negative microorganisms in adultused in combination with metronidazole ( ) Complicated Urinary Tract Infections (cUTI)+20
1990
NDA30/100
CERADON
cefotiam hydrochloride
LOE Approaching
Takeda
INJECTION · INJECTABLE
1988
NDA30/100
CEREBYX
fosphenytoin sodium
LOE Approaching
Pfizer
INJECTION · INJECTABLE
generalized tonic-clonic status epilepticusprevention+1
1996
NDA30/100